A breakthrough platform for C. difficile treatment and prevention

Introducing a therapeutic breakthrough: Our innovative treatment harnesses the power of Antibody-Enriched Eggs designed to selectively target and neutralize C. difficile pathogens.

  1. Superior Efficacy: Outperforms conventional antibiotics in treating active C. difficile infections, delivering faster and more reliable results.

  2. Prevents Recurrence: Synergizes with antibiotic therapy to disrupt the infection cycle, reducing relapse rates and promoting long-term gut health.

  3. Proactive Prevention: The first-ever preventive solution for high-risk populations, offering preemptive protection against C. difficile colonization.

This triple-action approach redefines infection management—treating active cases, blocking recurrence, and safeguarding vulnerable individuals.

 
 
 
 
 

The Science Behind our platform

Our platform integrates cutting-edge biotechnology with precision delivery to combat C. difficile infections (CDIs) at their source. Here’s how it works:

  1. Antibody Development & Scalable Egg Production
    We engineer highly specific antibodies designed to neutralize C. difficile toxins and disrupt bacterial colonization. These antibodies are produced sustainably using a proprietary avian (egg-based) system, which enables rapid, cost-effective scaling while maintaining therapeutic consistency.

  2. Precision Targeting of C. difficile
    The antibodies bind to key virulence factors, such as toxin B (TcdB) and surface proteins, blocking toxin-mediated damage to intestinal cells and preventing bacterial adhesion. This dual-action mechanism minimizes collateral harm to beneficial gut flora, addressing a critical flaw in broad-spectrum antibiotics.

  3. Oral Delivery via Egg Consumption
    Antibodies are delivered orally through consumption of antibody-rich eggs, leveraging the natural stability of avian IgY antibodies in the gastrointestinal tract. This method ensures targeted release in the gut, bypassing degradation in the stomach and enabling direct interaction with C. difficile. The approach is non-invasive, patient-friendly, and avoids risks associated with fecal transplants or systemic drugs.

By combining antibody specificity, scalable production, and gut-focused delivery, our platform offers a revolutionary strategy to treat and prevent CDIs while restoring microbiome health.

 
 
 
 
 
 

Why Our Platform Redefines Infection Control

1. Nature Meets Precision: Safe, Whole-Food Defense
“Harnessing bioactive nutrition with scientific rigor.”

  • Natural & Safe: Utilizes whole eggs—a familiar, nutrient-dense food source—enhanced through humane immunization. Free from synthetic additives and validated by rigorous safety protocols.

  • Dual Advantage: Combines eggs’ inherent health benefits with pathogen-specific immunoglobulins, creating a therapy that’s as gentle as it is potent.

2. Clinically Validated Power
“Science you can trust, results you can see.”

  • Proven Efficacy: Antibodies demonstrated >90% toxin neutralization in preclinical models, outperforming standard treatments in blocking bacterial adhesion and toxin activity.

  • Peer-Reviewed Confidence: Published studies confirm sustained protection against hypervirulent C. difficile strains (e.g., BI/NAP1/027).

3. Three-Pillar Protection
“The first solution to attack the infection lifecycle at every stage.”

  • Comprehensive Action:

    • Cures by directly neutralizing toxins and bacteria.

    • Guards against relapse by targeting bacteria spores.

    • Prevents colonization in high-risk patients (e.g., post-antibiotic or hospitalized individuals).

4. Scalable, Sustainable Impact
“Affordability meets accessibility.”

  • Cost-Effective: Egg-based production cuts drug development costs by 60% vs. synthetic biologics, with no cold-chain requirements.

  • Global Reach: Simplified manufacturing enables rapid scale-up to meet urgent clinical and prophylactic needs.

Beyond Innovation—A New Standard
While others treat symptoms, our platform rewrites the rules: a food-based delivery system delivering hospital-grade protection. It’s not just a therapy—it’s a paradigm shift in how we combat antimicrobial resistance.

Scroll to Top